Lazertinib Mesylate
FDA-approved product (tablet, oral), marketed as Lazcluze.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Non-small cell lung carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
- FDA pharmacologic class
- Kinase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA66.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lazertinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- BicalutamideExisting use: Carcinoma, Neoplasm65.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents65.1% AI-predicted activityagainst M. tuberculosis1 registered study
- Avatrombopag MaleateExisting use: Hemorrhage, Liver disease, Thrombocytopenia65.0% AI-predicted activityagainst M. tuberculosis6 registered studies
- BumetanideExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more64.9% AI-predicted activityagainst M. tuberculosis49 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease64.9% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ThioridazineExisting use: Psychosis64.8% AI-predicted activityagainst M. tuberculosis11 registered studies
- MethyclothiazideExisting use: Cardiovascular disease64.7% AI-predicted activityagainst M. tuberculosis5 registered studies
- FurosemideExisting use: Cardiovascular disease, Cirrhosis of liver, Congestive heart failure and 5 more64.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- EnzalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 4 more64.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more64.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm64.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- LemborexantExisting use: Insomnia64.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.